Search Results
Your search for ,USE matches 11256 pages
Showing 7251 - 7300Lenalidomide/Dexamethasone in High-Risk Smoldering Multiple Myeloma
Long-term follow-up in the phase III QuiRedex trial indicates continued benefit of lenalidomide (Revlimid)/dexamethasone vs observation in preventing disease progression in patients with high-risk smoldering multiple myeloma, as reported by Maria-Victoria Mateos, PhD, of Instituto de Biologia...
Expect Questions About the FDA Discouraging Use of Ovarian Cancer Screening Tests
The release of a U.S. Food and Drug Administration (FDA) Safety Communication “alerting women about the risks associated with the use of tests being marketed as ovarian cancer screening tests”1 and recommending against using these tests comes not as a result of startling new studies, but from an...
The FDA Urges Physicians and Patients to Forgo Ovarian Cancer Screening Tests
In a Safety Communication directed at women and physicians, the U.S. Food and Drug Administration (FDA) alerted women “about the risks associated with the use of tests being marketed as ovarian cancer screening tests” and recommended “against using currently offered tests to screen for ovarian...
ASCO Supports Recent Tobacco Legislation
On August 8, the U.S. Food and Drug Administration’s (FDA) rule giving the agency the authority to regulate e-cigarettes, cigars, hookahs, and pipe tobacco took effect. In May, ASCO applauded the FDA for exercising its congressionally mandated authority to regulate e-cigarettes as a crucial step in ...
Are You Ready for MACRA? ASCO Offers Educational Resources and Events to Help Practices Prepare
There are only a few months to go before program changes go into effect under the Medicare Access and CHIP Reauthorization Act (MACRA) on January 1, 2017. MACRA was enacted more than a year ago to replace the Sustainable Growth Rate formula for updates to the Medicare physician fee schedule, and it ...
Particular HPV Strain Linked to Improved Prognosis for Oropharyngeal Cancer
When it comes to cancer-causing viruses like human papillomavirus (HPV), researchers are continuing to find that infection with one strain may be better than another. In an analysis of survival data for patients with oropharyngeal cancer, researchers from the University of North Carolina (UNC)...
A Helping Hand, Just in Time: The ASCO Guideline for Managing Chronic Pain in Adult Cancer Survivors
With impeccable timing, as well as considerable forethought and planning, Dr. Paice and colleagues have produced a superb evidence-based guideline on “Management of Chronic Pain in Survivors of Adult Cancers.”1 (See this issue of The ASCO Post.) This summary of well-informed and thoroughly...
ASCO Clinical Practice Guideline on Management of Chronic Pain in Survivors of Adult Cancers
As reported in the Journal of Clinical Oncology by Judith A. Paice, PhD, RN, of Northwestern University, and colleagues, ASCO has released a clinical practice guideline on management of chronic pain in survivors of adult cancers.1 The guideline was based on literature review by an expert panel,...
Amelie G. Ramirez, DrPH, Receives AACR Distinguished Lecture on the Science of Cancer Health Disparities
The American Association for Cancer Research (AACR) Distinguished Lecture on the Science of Cancer Health Disparities, funded by Susan G. Komen, honors an investigator whose novel and significant work has had or may have a far-reaching impact on the etiology, detection, diagnosis, treatment, or...
Which Factors Influence Radiotherapy for Brain Metastases?
The advent of more effective systemic therapies, which extend patients’ lives, has also resulted in an increasing incidence of brain metastases, for which clinicians must determine appropriate treatment. Whole-brain radiotherapy has been the traditional treatment modality, but stereotactic...
Friends of Cancer Research Honors Oncology Leaders at 20th Anniversary and Announces Partnership
Friends of Cancer Research (Friends) celebrated its 20th anniversary September 21 at a special event in Washington, DC. The event honored Janet Woodcock, MD; Eric Lander, PhD; and Sean Parker. Dr. Woodcock, Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug...
Clinical Trials Actively Recruiting Patients With Early Breast Cancer
Pilot Study Title: Pilot Trial of an Implantable Microdevice for in Vivo Drug Sensitivity Testing in Patients With Early-Stage, HER2-Positive, or Triple-Negative Breast Cancer Receiving Neoadjuvant Therapy Study Type: Pilot/interventional/single-group assignment Study Sponsor and Collaborators:...
Using Watson to Analyze Genomic Data to Personalize Treatment for Patients With Cancer
Three years ago, IBM’s Watson supercomputer was best known for defeating two former champions on the TV game show Jeopardy! Today, it is grabbing headlines for becoming an important assistant in cancer care. Able to read and understand millions of pages of text within seconds, Watson caught the...
Internationally Renowned Statistician on Cancer Clinical Trials, Daniel J. Sargent, PhD, Dies
In the 20th century, the field of statistics developed and was gradually applied to clinical research. The use of statistics allows clinical researchers to form reasonable and accurate inferences from collected information and to make sound decisions in the presence of uncertainty. Moreover,...
Palliative Care: Let’s Use the Tools We Already Have
Clinicians and researchers in the field of palliative and supportive care are enjoying the recognition the field is now receiving and expecting the future to be ripe with opportunity. But one thought leader in this specialty had a suggestion for attendees at the 2016 Palliative Care in Oncology...
Pearls for Managing Immune-Related Toxicities
With checkpoint inhibitors in frequent use, clinicians strive daily to balance the efficacy and toxicity of these treatments. At the 2016 Palliative Care in Oncology Symposium, Lynn M. Schuchter, MD, FASCO, the C. Willard Professor of Hematology-Oncology at the University of Pennsylvania,...
Immunotherapy Brings Unique Challenges for Clinicians
The advent of immunotherapies has created a number of interesting challenges for oncology providers. At the 2016 Palliative Care in Oncology Symposium, specialists in the field tackled these issues. “There is a lot of newness to how we approach patient care with immunotherapies on board,” said...
Why Curing Cancer Will Take Decades
This past summer, Eric S. Lander, PhD, President of the Broad Institute of the Massachusetts Institute of Technology and Harvard in Cambridge, Massachusetts, and Co-Chair of the President’s Council of Advisors on Science and Technology, raised a few eyebrows at the Aspen Ideas Festival when he...
Update on Neoplastic Hematology: Review of Recent Clinical Trials
Here is a brief look at the study findings and clinical implications of several recent clinical trials on newer treatment options in neoplastic hematology. Attention is focused on several types of leukemia, Hodgkin lymphoma, and multiple myeloma. Leukemia Clinical Trial: INO-VATE ALL phase III...
Salk Institute’s Clodagh O’Shea, PhD, Named Howard Hughes Medical Institute Faculty Scholar
Clodagh O’Shea, PhD, Associate Professor in the Salk Institute’s Molecular and Cell Biology Laboratory, is among the first recipients of a grant from the Faculty Scholars Program, a new partnership of Howard Hughes Medical Institute (HHMI), the Bill and Melinda Gates Foundation, and the Simons...
AACR’s Cancer Progress Report Hails Research Advances and Details Challenges Ahead
Although research advances in more effective therapies and diagnostics and improved screening technology over the past 2 decades have led to a 23% reduction in the cancer death rate in the United States, saving nearly 2 million lives,1 cancer remains the second leading cause of death after heart...
Surgery and Radiation ProtecT Against Progression/Metastasis vs Active Monitoring in Prostate Cancer, but at What Cost?
The ProtecT trial showing similar 10-year survival with active monitoring, surgery, or radiotherapy for prostate-specific antigen (PSA)-detected localized prostate cancer but a greater risk of disease progression/metastasis with monitoring was recently reported by Hamdy and colleagues and is...
Risk of Metastasis With Active Monitoring in PSA-Detected Localized Prostate Cancer: The ProtectT Trial
The ProtecT study findings1 are provocative. Despite having a control arm of active monitoring with serial prostate-specific antigen (PSA) testing, as compared with watchful waiting in the prior randomized trials (ie, SPCG-42 and PIVOT3), and also enrolling men with more favorable-risk disease...
Phase II Trial Shows Benefit of Ibrutinib in Relapsed/Refractory CLL With 17p Deletion
O’Brien et al found further evidence of the benefit of ibrutinib (Imbruvica) in relapsed/refractory chronic lymphocytic leukemia (CLL) with the 17p deletion, according to an extended analysis of the phase II RESONATE-17 trial reported in The Lancet Oncology. Ibrutinib currently is approved...
ASTRO 2016: SBRT Offers Patients With Prostate Cancer High Disease Control and Low Toxicity in Fewer Treatments
High-dose stereotactic body radiotherapy (SBRT) for men newly-diagnosed with low- or intermediate-risk prostate cancer results in shorter treatment times, low severe toxicity, and excellent cancer control rates, according to research presented by Meier et al at the 58th Annual Meeting of the...
ASTRO 2016: Hypofractionated Radiation Therapy May Halve Treatment Time for Lung Cancer Patients With Poor Performance Status
For patients with stage II and III non–small cell lung cancer (NSCLC) unable to receive standard treatments of surgery or chemoradiation, hypofractionated radiation therapy results in similar overall survival and progression-free survival rates, limited severe side effects, and shorter...
Study Finds Statin Use Associated With Reduced Mortality in Multiple Myeloma
Analysis of data from the Veterans Administration Central Cancer Registry, reported in the Journal of Clinical Oncology by Sanfilippo et al, showed that statin use was associated with a reduced risk of all-cause and multiple myeloma–specific mortality in patients with multiple myeloma....
ASTRO 2016: Advances in Radiation Therapy Have Improved Survival Rates for Patients With Early-Stage Lung Cancer
A new analysis of records in the Veterans Affairs Central Cancer Registry demonstrates a clear positive impact of the increased use of stereotactic body radiation therapy (SBRT) to treat patients with stage I non–small cell lung cancer (NSCLC) in recent years, according to research presented...
ASTRO 2016: Radiation Boost Reduces Local Tumor Recurrence for Patients With DCIS Following WBRT
A supplemental “boost” of radiation improves local control and provides an incremental benefit in decreasing breast cancer recurrence for patients with ductal carcinoma in situ (DCIS) who receive whole breast radiation therapy radiation (WBRT) following lumpectomy, according to research ...
ASTRO 2016: Intermediate-Risk Prostate Cancer May Be Well Controlled With Brachytherapy Alone
For men with intermediate-risk prostate cancer, radiation treatment with brachytherapy alone can result in similar cancer control with fewer long-term side effects, when compared to more aggressive treatment that combines brachytherapy with external beam therapy (EBT), according to research...
ASCO/ASTRO/SSO Develop Focused Guideline Update on Postmastectomy Radiotherapy
As reported by Recht et al in the Journal of Clinical Oncology, a joint ASCO, American Society for Radiation Oncology (ASTRO), and Society of Surgical Oncology (SSO) panel has developed a focused guideline update of the ASCO guideline on postmastectomy radiotherapy. A recent Cancer Care Ontario...
ASTRO 2016: Widespread Adoption of SBRT Has Improved Survival Rates for Elderly Patients With Early-Stage Lung Cancer
Survival rates for elderly patients who received stereotactic body radiation therapy (SBRT) for early stage non–small cell lung cancer (NSCLC) rose from roughly 40% to 60% over the past decade, concurrent with the increasing adoption of SBRT, according to research presented by Dalwadi et al...
ASTRO 2016: Cervical and Endometrial Cancer Patients Report Fewer Side Effects and Better Quality of Life With IMRT
Patients with cervical and endometrial cancer have fewer gastrointestinal and genitourinary side effects and experience better quality of life when treated with intensity-modulated radiation therapy (IMRT) than with conventional radiation therapy, according to research presented by Klopp et al at...
Ratio of Certain Immune Cells in the Blood to Tumor Burden Correlated With Outcome for Melanoma Patients Treated With Pembrolizumab
Although some patients with melanoma experience durable responses to treatment with the anti–PD-1 (programmed cell death protein 1) therapy pembrolizumab (Keytruda), the majority of patients do not experience a durable clinical benefit from anti–PD-1 monotherapy, according to a study by ...
Daniel Hamstra, MD, PhD, on Prostate Cancer: Decreasing Rectal Toxicity 126
Daniel A. Hamstra, MD, PhD, of Texas Oncology, discusses phase III findings on the use of an absorbable hydrogel spacer designed to decrease rectal toxicity and improve bowel quality of life for patients with prostate cancer. (Abstract LBA-6)
Analysis Indicates Survival Advantage With Neoadjuvant Therapy in Resectable Pancreatic Cancer
In a propensity score–matched analysis of National Cancer Database data reported in the Journal of Clinical Oncology, Mokdad et al found that neoadjuvant therapy followed by resection was associated with a survival benefit vs upfront resection. Study Details The analysis included adults...
Study Confirms Benefit of Cobimetinib Plus Vemurafenib in Advanced BRAF V600–Mutant Melanoma
As reported by Ascierto et al in The Lancet Oncology, longer-term follow-up in the pivotal phase III coBRIM trial confirmed the benefit of adding cobimetinib to vemurafenib (Zelboraf) in first-line treatment of BRAF V600–mutant unresectable stage IIIC or IV melanoma. Grant A. McArthur, FRACP, of...
Olanzapine Combination Reduces Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy
According to a phase III trial reported by Navari et al in The New England Journal of Medicine, the addition of the antipsychotic agent olanzapine vs placebo to dexamethasone, aprepitant, or fosaprepitant, and a 5-hydroxytryptamine type 3–receptor antagonist reduced nausea and improved antiemetic...
The Anesthesia Era 1845–1875 Carte de Visite, London, circa 1858
For over 2,500 years, bloodletting was the backbone of medical therapy. To date, it is the longest-running therapeutic tradition known. First practiced in ancient Egypt, its use spread throughout Western civilization. The therapy was still performed in Southern rural America until the 1910s. One...
Cancer Moonshot Blue Ribbon Panel Recommends 10 Ways to Speed Cancer Advances
Earlier this month, members of the National Cancer Moonshot Initiative’s Blue Ribbon Panel submitted an ambitious list of 10 recommendations on the scientific approaches that are most likely to accelerate progress against cancer to the President’s National Cancer Advisory Board. The panel’s...
The Halifax Project: A New Approach to Combination Therapy
On August 13, 2013, more than 100 cancer researchers and physicians from around the world met in Halifax, Nova Scotia, Canada, to discuss 2 challenging problem areas in cancer. One group was focused on the carcinogenic potential of low-dose exposure to chemical mixtures in the environment, and the...
Pioneer in Chemoradiation Robert B. Livingston, MD, Dies
Over the past couple of decades, chemoradiation for several cancers, such as lung and breast, has advanced in efficacy and side-effect tolerance, prolonging survival and quality of life for patients. One of the pioneers in chemoradiation, Robert B. Livingston, MD, died on September 8, 2016. Dr....
FDA Approves Blinatumomab for Use in Pediatric Patients With Ph-Negative Relapsed or Refractory B-Cell Precursor ALL
The U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for blinatumomab (Blincyto) to include new data supporting the treatment of pediatric patients with Philadelphia chromosome (Ph)-negative relapsed or refractory B-cell precursor acute...
ASCO Continues Active Involvement in Cancer Moonshot
This summer, ASCO continued its active involvement in Vice President Joe Biden’s Cancer Moonshot Initiative. ASCO joined the Vice President at the formal launch of the moonshot earlier this year, and since then, has discussed research and policy proposals to advance discovery in cancer treatment...
Breaking the ‘Conspiracy of Silence’
A new study1 showing that just 1 in 20 terminally ill patients with cancer has sufficient understanding about the prognosis or purpose of treatment is highlighting the need for improvements in both the way oncologists communicate prognosis with their patients and in the development of educational...
The Role of Music Therapy in Cancer Care
Music therapy, an established adjuvant to standard cancer care, is offered in a growing number of cancer centers throughout the United States and internationally. Defined by the American Music Therapy Association (AMTA) as “the evidence-based use of music interventions to accomplish individual...
Improving Management of Sexual Problems for Cancer Survivors
What do up to 60% of cancer survivors have in common? Answer: some type of long-term sexual dysfunction. How many cancer survivors seek professional help for sexual problems? Answer: less than 20%. Even when they do seek help, they may not be successful in finding professionals with expertise in...
Why Patients’ Understanding of Their Prognosis Often Differs From Their Oncologists’
A recent study1 published in the Journal of Clinical Oncology (see “Breaking the ‘Conspiracy of Silence’” in this issue of The ASCO Post) found that just 1 in 20 patients with advanced, incurable cancer has sufficient understanding of his or her prognosis or life expectancy. Now, another new study ...
FDA Takes Action Against 55 Tobacco Retailers for Selling Newly Regulated Products to Minors
The U.S. Food and Drug Administration (FDA) announced on September 15 that it has taken action against 55 tobacco retailers by issuing the first warning letters for selling newly regulated tobacco products—such as e-cigarettes, e-liquids, and cigars—to minors. These actions come about a month after ...
I-SPY 2: Separating Contenders From Pretenders in Breast Cancer
With the expansion of our understanding of signaling pathways in normal cells and how they are co-opted or corrupted in malignancy, the number of potential antitumor agents to be tested has exploded, exposing the limitations of traditional antineoplastic drug development and challenging us to...
